Company Overview - Meinuohua, established on February 19, 2004, and listed on April 7, 2017, is located in Ningbo, Zhejiang Province. The company specializes in the research, production, and sales of specialty raw materials (including intermediates) and finished pharmaceuticals [1][2]. Financial Performance - For the first half of 2025, Meinuohua achieved a revenue of 677 million yuan, representing a year-on-year growth of 11.42%. The net profit attributable to shareholders was 49.06 million yuan, showing a significant increase of 158.97% [2]. - Since its A-share listing, Meinuohua has distributed a total of 149 million yuan in dividends, with 50.58 million yuan distributed over the past three years [3]. Stock Performance - As of September 9, Meinuohua's stock price was 25.20 yuan per share, with a market capitalization of 5.54 billion yuan. The stock has increased by 99.05% year-to-date, but has seen a decline of 1.72% over the past five trading days and 12.10% over the past 20 days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) six times this year, with the most recent appearance on August 28, where it recorded a net buy of -113 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Meinuohua was 32,400, an increase of 17.14% from the previous period. The average number of circulating shares per shareholder was 6,590, a decrease of 14.63% [2]. - Notably, some institutional investors, including融通健康产业灵活配置混合A/B and 光大保德信信用添益债券A类, have exited the list of the top ten circulating shareholders [3]. Business Segments - The company's revenue composition includes 57.74% from intermediates and raw materials, 29.53% from formulations, 8.87% from CDMO (Contract Development and Manufacturing Organization), 3.52% from trade, and 0.34% from other sources [1]. Industry Classification - Meinuohua is classified under the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and raw material drug sectors. It is associated with concepts such as assisted reproduction, hepatitis treatment, pet economy, raw materials, and small-cap stocks [2].

Group 1 - The company will hold a half-year performance briefing on September 16, 2025, from 09:30 to 11:30 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live stream and online interaction [3][4] - Investors can submit questions from September 9 to September 15, 2025, and the company will address common concerns during the briefing [2][4][3] Group 2 - Key participants in the briefing include the Chairman and General Manager, Yao Chengzhi, and the Secretary of the Board and Financial Officer, Ying Gaofeng [4] - Investors can access the briefing through the Shanghai Stock Exchange Roadshow Center website [4][6] - After the briefing, investors can review the main content and proceedings on the Roadshow Center website [6][7]

Group 1 - The company, Meinuohua, announced plans to hold a semi-annual performance briefing on September 16, 2025, from 09:30 to 11:30 [2]

| | | 宁波美诺华药业股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 16 日 （星期二） 09:30-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 本次投资者说明会以视频结合网络互动召开，公司将针对 2025 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 09 月 16 日 （星期二） 09:30-11:30 （二）会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频直播和网络互动 三、 参加人员 董事长兼总经理：姚成志 董事会秘书兼财务负责人：应高峰 ...

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Group 1 - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted, allowing him to resume his duties, which enhances investor confidence in the company's future development [1] - FTSE Russell announced the inclusion of BeiGene and WuXi AppTec in the FTSE China A50 Index, reflecting the increasing importance of A-share companies in the global capital market and foreign investment interest in China's innovative drug sector [2] - Otsuka Pharmaceutical's application for the targeted drug, Belimumab injection, for IgA nephropathy has been accepted, potentially filling a market gap in a field with limited treatment options and providing a new growth point for the company [3] Group 2 - Ruizhi Pharmaceutical announced a partnership to establish a fund focused on investing in innovative drugs and medical devices, which will enhance the company's resource reserves and align with current industry trends [4] - Menova's subsidiary has received approval for Mosapride Citrate Tablets in China, which is expected to generate new revenue growth for the company and strengthen its position in the pharmaceutical industry [5]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Group 1 - The company’s subsidiary, Ningbo Meinuo Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration, allowing it to produce and sell the drug in the domestic market [1][2] - The drug is indicated for improving gastrointestinal symptoms caused by reduced gastrointestinal motility, such as functional dyspepsia and chronic gastritis [1] - The global sales forecast for Mosapride Citrate Tablets in 2024 is approximately $16.53 million, with China accounting for about $5.28 million of that total [1] Group 2 - The approval of the drug enhances the company's market competitiveness and enriches its gastrointestinal product pipeline, positively impacting its operational development [2] - The future sales of the drug may be influenced by various uncertain factors, including policy changes, market demand, and competition from similar products [2]

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration [2] Group 1 - The approval of the drug registration certificate marks a significant milestone for the company in expanding its product portfolio [2] - Mosapride Citrate is expected to enhance the company's competitive position in the pharmaceutical market [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]